Home » Topics » Regulatory » EMA

EMA
RSS

First vaccine candidate for malaria accepted for E.U. regulatory review

July 25, 2014

EMA accepts MAA for asfotase alfa as a treatment for hypophosphatasia

July 25, 2014

Sunesis Pharmaceuticals receives positive opinion on pediatric investigation plan for vosaroxin

July 10, 2014

Teva Pharmaceutical receives positive CHMP opinion for Seasonique

July 7, 2014

EMA accepts for review Merck & Co.'s MAA for anti-PD-1 MAb pembrolizumab

July 1, 2014

CHMP recommends Velphoro for control of serum phosphorus levels in adults with CKD

July 1, 2014

EMA committee recommends approval of Triumeq

July 1, 2014

Bevacizumab recommended for E.U. approval in new indication

July 1, 2014

EMA committee hands down positive opinion on Eylea for DME

July 1, 2014

EMA committee recommends approval of Abasria

June 30, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...